Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cenobamate adjunctive therapy for partial onset seizures
jRCT2031200405Phase 3Completed
- Sponsor
- SK Life Science, Inc.
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of cenobamate in Focal onset seizure (4 arms), sponsored by SK Life Science, Inc. Primary endpoint: Median percent change from baseline in seizure frequency. Started May 2021; status: completed.
02
Drugs
cenobamate
03
Conditions
Focal onset seizure
Beyond the preview
Go deeper on jRCT2031200405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200405.